US · Healthcare · Biotechnology
EPS came in at -0.73 against a street estimate of -0.81 — a beat of 9.9%.
Analysts rate Rhythm Pharmaceuticals Inc a strong buy (12 buy, 0 hold, 0 sell out of 12) with an average price target of $140.19.
CONFIDENT Strong HO launch with 400+ start forms in 14 weeks; RM-718 shows comparable efficacy to setmelanotide with no hyperpigmentation; Q2 revenue $71.3M (+47% YoY); cash position $331M supports 24+ months operations. Q2 2026 International revenue declined Q2 vs Q1 due to $3.8M French contribution mechanism charge (mostly 2025-related). Europe HO launches anticipated in 2027 starting Germany H1; Japan approval and launch expected by year-end 2026. Analysts probed launch sustainability (no bolus evident), HO vs. BBS discontinuation rates (HO lower expected), PWS asset choice (CMC-driven, both possible), and GLP-1 competition (50% prior exposure, different mechanism). Management emphasized precision medicine positioning, breadth metrics, and multi-asset optionality rather than single-drug strategy. 2026-08-04…
Full summary in the app.
| Fund | Stake |
|---|---|
| RA Capital Management, LLC | 9.68% |
| BlackRock Inc | 9.06% |
| Baker Bros Advisors LP | 8.14% |
| PRIMECAP Management Company | 4.60% |
| Vanguard Portfolio Management, LLC | 4.42% |
| Vanguard Capital Management, LLC | 4.31% |
| Perceptive Advisors LLC | 3.76% |
| State Street Corp | 3.30% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 RHYTHM PHARMACEUTICALS, INC. – FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Product Revenue (6 months 2026): $131.4 mil | 2026-08-04 |
| Results announced · Q3 2026 RHYTHM PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 product revenue: $71.3 million (up 19% sequentially from Q1 2026; up 47% | 2026-08-04 |
| Shareholder vote results · Q2 2026 RHYTHM PHARMACEUTICALS, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual Meeting held June 24, 2026 • 68,530,107 shares of common stock outstanding | 2026-06-25 |
| Reg FD disclosure · Q2 2026 RHYTHM PHARMACEUTICALS, INC. – FORM 8-K SUMMARY HEADLINE NUMBERS • Prader-Willi Syndrome (PWS) Phase 2 Trial – 6-Month Interim Data: - 18 patients | 2026-06-15 |
| Quarterly report · Q1 2026 RHYTHM PHARMACEUTICALS, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash & Short-term Investments: $340.6 million as of March 31, 2026 ($62.1 mil | 2026-05-05 |
| Results announced · Q2 2026 RHYTHM PHARMACEUTICALS Q1 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • Q1 2026 Product Revenue: $60.1 million (up 5% sequentially from Q4 2025; up 59% | 2026-05-05 |
| Proxy statement · Q2 2026 RHYTHM PHARMACEUTICALS, INC. – PROXY STATEMENT SUMMARY --- CEO COMPENSATION & CHANGES • David P. Meeker, M.D. (Chairman, President, and CEO) – Tota | 2026-04-29 |
| Annual report FY2025 RHYTHM PHARMACEUTICALS, INC. – FORM 10-K SUMMARY Fiscal Year Ended December 31, 2025 --- HEADLINE NUMBERS • Total product sales to date: Approximat | 2026-02-26 |
Readable in the app.
| Announcement | Date |
|---|---|
| FDA Approval of IMCIVREE for Acquired Hypothalamic Obesity Rhythm Pharmaceuticals announced FDA approval of IMCIVREE (setmelanotide) for treating acquired hypothalamic obesity (AHO), a rare disease causing severe weight gain from hypothalamic injury | 2026-03-20 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Rhythm Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-09-18.